Fig. 2From: Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case reportBRCA2 reversion mutations. Schematic of small indel (a) and large deletion mutations (b) detected. BRC repeats, interacting regions, and sequences are represented as yellow, blue, and orange boxes, respectively. Substitutions and deletions are represented as red text and black lines, respectivelyBack to article page